Page last updated: 2024-11-05

troglitazone and Peripheral Vascular Diseases

troglitazone has been researched along with Peripheral Vascular Diseases in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Peripheral Vascular Diseases: Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.

Research Excerpts

ExcerptRelevanceReference
" The occult diabetic group had an abnormal response to hyperemia before the treatment with troglitazone and showed little change in flow after BA occlusion."3.70Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. ( Avena, R; Curry, KM; Mitchell, ME; Nylen, ES; Sidawy, AN, 1998)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Avena, R1
Mitchell, ME1
Nylen, ES1
Curry, KM1
Sidawy, AN1

Other Studies

1 other study available for troglitazone and Peripheral Vascular Diseases

ArticleYear
Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.
    Journal of vascular surgery, 1998, Volume: 28, Issue:6

    Topics: Aged; Blood Flow Velocity; Brachial Artery; Chromans; Fasting; Glucose Intolerance; Glucose Toleranc

1998